Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule

Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule

Lung cancer is one of the most common malignancies with the highest incidence rate and mortality rate worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85%. Only 5% NSCLC patients are anaplastic lymphoma kinase (ALK) rearrangement positive NSCLC, but the prognosis of these patient...

Full description

Bibliographic Details
Main Authors: Yang WANG, Xiaobin YUAN, Jiayan Xiong, Zhidong HAO, Xingzhe PENG, Wanlin CHEN, Lingling CUI, Hua LI, Xiulan WANG, Xiangbo HE, Min YANG, Congxin LIANG, Yongbin Ma, Lieming DING, Li MAO
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
ensartinib
lung noplasms
anaplastic lymphoma kinase tyrosine kinase inhibitor
clinical studies
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.34

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.34

Similar Items